Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research, said Eli Lilly is weighing next steps for ...

But since the start of last year, two Alzheimer's treatments have been approved in the United States: Biogen's lecanemab and Eli Lilly's donanemab. They work by targeting the build-up of two proteins ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

1 Donanemab is approved under the brand name Kisunla™ in the United States, Japan, Great Britain and other countries. These data were presented at Eli Lilly and Company (NYSE: LLY) announced results ...